Drug Trial Radar · NCT07620405
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
219
Planned (sponsor's estimate)
Start
Jul 2027
Primary completion
Jan 2030
Study completion Jan 2031
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
Conditions
- Thyroid Eye Disease (TED)
Interventions
MHB018A injectionDrug
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate at Week 24Time frame: Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.